Similarly, elevated EphA2 expression indicated a poor prognosis for patients with colon adenocarcinoma (COAD), diffuse large B-cell lymphoma (DLBC), low-grade glioma (LGG), and pancreatic adenocarcinoma (PAAD), yet correlated with higher survival rates in those with kidney chromophobe (KICH) and pheochromocytoma and paraganglioma (PCPG). This evidence concerns the gene EPHA2 and low grade glioma.